Copenhagen, 2015-12-14 10:00 CET (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ Copenhagen: “EXQ”) today announced the expected dates for Exiqon A/S’ annual general meeting and financial reporting in 2016.
| Deadline for shareholders’ proposal to the annual general meeting: | 3 February 2016 |
| Announcement of full year's results | 8 February 2016 |
| Annual general meeting 2016 | 16 March 2016 |
| Interim report 1 January - 31 March 2016 | 26 April 2016 |
| Interim report 1 April - 30 June 2016 | 23 August 2016 |
| Interim report 1 July - 30 September 2016 | 19 October 2016 |
Additional information
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
About Exiqon
Exiqon operates in two business areas: Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. Exiqon is listed on NASDAQ in Copenhagen. For more information about us, please visit www.exiqon.com
